Definitive Healthcare (DH) earnings call transcripts

Management framed the quarter as progress toward a recovery led by diversified and provider markets, while life sciences remained slower than expected.

Management framed the quarter as evidence that retention and execution initiatives are working, while life sciences remains the main obstacle to returning to growth.

Management framed 2025 as stabilization after claims disruption, with retention recovery and product-led growth expected to build gradually through 2026.

Management framed Q3 as operational progress, but stressed that December–January renewals and life-sciences expansion pressure still constrain the path back to growth.